By performing myocardial perfusion imaging (MPI) with cardiac FDG-PET before revascularization, clinicians can better assess the benefits of that procedure and predict near-term outcomes for patients with coronary artery disease and left ventricular dysfunction, according to a study presented on Sunday at RSNA 2018.... Read More
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) submitted a letter to BlueCross BlueShield (BCBS) of Tennessee urging an expansion of cardiac PET coverage.
GE Healthcare and Lantheus Medical Imaging have launched a second phase III clinical trial for Lantheus' flurpiridaz F-18 investigational PET radiopharmaceutical.
Florbetapir-PET scans show that midlife adults with two or more vascular risk factors are significantly more likely to have greater levels of amyloid deposits in their brains later in life than peers with no such risk factors, according to a study published April 11 in the Journal of the American Medical... Read More
Heart disease is a danger like no other, meaning proper diagnosis is of paramount importance. PET scans have been, and continue to be, the best way to get such a diagnosis.
POSITRON ANNOUNCES SALE OF ATTRIUS PET SCANNER
Niagara Falls, NY –September 5, 2018 – Positron Corporation (OTC:POSC)(the “Company”), a nuclear medicine healthcare company, is pleased to announce the sale of its Attrius PET scanner to a prominent cardiology practice in the US as they expand their services to... Read More
